Faculty

Lisa A. Kottschade, APRN, C.N.P.

Clinical Studies

Antineoplastic Pilot Study Rochester, Minn.
The purpose of this study is to use therapeutic drug monitoring (trough plasma concentrations of dabrafenib, hydroxy dabrafenib, and/or trametinib) along with CYP3A4/CYP3A5 and CYP2C8 genotyping and BRAF mutation quantification will correlate with effectiveness (based on imaging studies) and/or toxicity (pyrexia, liver dysfunction, rash) in known melanoma patients.

A US Multi-Site Observational Study in Patients with Unresectable And Metastatic Melanoma: The OPTIMIzE Study Rochester, Minn.
The purpose of this study is to describe the demographics, clinical characteristics and different patterns of care for patients who have unresectable or metastatic melanoma. The dosing, duration, regimen, indication, and treatments will be observed. The survival rate of these patients will also be observed.